- Home
- MEGL vs SNTI Comparison
MEGL vs SNTI Comparison
Compare MEGL & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- SNTI
- Stock Information
- Founded
- MEGL 2016
- SNTI 2016
- Country
- MEGL Hong Kong
- SNTI United States
- Employees
- MEGL N/A
- SNTI N/A
- Industry
- MEGL Finance: Consumer Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- MEGL Finance
- SNTI Health Care
- Exchange
- MEGL Nasdaq
- SNTI Nasdaq
- Market Cap
- MEGL 9.0M
- SNTI 10.4M
- IPO Year
- MEGL 2022
- SNTI N/A
- Fundamental
- Price
- MEGL $0.49
- SNTI $2.29
- Analyst Decision
- MEGL
- SNTI
- Analyst Count
- MEGL 0
- SNTI 0
- Target Price
- MEGL N/A
- SNTI N/A
- AVG Volume (30 Days)
- MEGL 393.7K
- SNTI 16.0K
- Earning Date
- MEGL 10-30-2024
- SNTI 11-26-2024
- Dividend Yield
- MEGL N/A
- SNTI N/A
- EPS Growth
- MEGL N/A
- SNTI N/A
- EPS
- MEGL N/A
- SNTI N/A
- Revenue
- MEGL $1,976,138.00
- SNTI $338,000.00
- Revenue This Year
- MEGL N/A
- SNTI $254.47
- Revenue Next Year
- MEGL N/A
- SNTI $169.66
- P/E Ratio
- MEGL N/A
- SNTI N/A
- Revenue Growth
- MEGL 67.75
- SNTI N/A
- 52 Week Low
- MEGL $0.41
- SNTI $1.52
- 52 Week High
- MEGL $1.47
- SNTI $7.43
- Technical
- Relative Strength Index (RSI)
- MEGL 47.05
- SNTI 49.58
- Support Level
- MEGL $0.48
- SNTI $2.12
- Resistance Level
- MEGL $0.57
- SNTI $2.32
- Average True Range (ATR)
- MEGL 0.04
- SNTI 0.15
- MACD
- MEGL 0.00
- SNTI 0.02
- Stochastic Oscillator
- MEGL 29.25
- SNTI 43.18
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.